Mersana Therapeutics (MRSN) Misses Q2 EPS by $4.71

Mersana Therapeutics (NASDAQ: MRSN) reported Q2 EPS of ($4.87), $4.71 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $3.06 million versus the consensus estimate of $6.25 million.

For earnings history and earnings-related data on Mersana Therapeutics (MRSN) click here.

You May Also Be Interested In

• Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
• Bernstein SocGen Group Reiterates Outperform Rating on Zydus Lifesciences (ZYDUSLIF:IN)
• Micropolis Robotics displays autonomous robots at Dubai investment event